Combining SII with serum PSA can address the limitations of using SII or PSA alone, enhancing the diagnostic efficacy for both prostate cancer and metastatic prostate cancer, and providing valuable information for the early diagnosis and treatment of prostate cancer. Here, KLK3 is linked to prostate cancer.